Introduction

• Title
• Disclaimer
• Certification
• Table of Contents

Executive Summary

• Competing in the U.S. CRO Market

Objectives and Methodology

• Objectives of the Study
• Methodology

Outsourcing Patterns and Trends

• Percent of Pharmaceutical and Biotechnology Outsourcing - By Research Area
• Percent Clinical Development Outsourcing: Current and Future
• Research and Development Budget
• Percent R&D Budget Allocated to CRO Expenditures
• Percent Increase in CRO Budget Next 12-24 Months
• Percent Share of Phases in CRO Budget - Current and Projected

Motives and Perceived Benefits of Outsourcing

• Perceived Benefits of Outsourcing

CRO Utilization Satisfaction and Preferences

• Oncology
• Central Nervous System (CNS)
• Cardiovascular
• Metabolic Diseases
• Infectious Diseases
• Respiratory/Allergy
• Musculoskeletal/Arthritis
• Full-Service CRO Preferences
• Niche CRO Preferences
• Pre-Clinical Phase Preferences
• Phase I Preferences
• Phase II/III Preferences
• Phase IV Preferences

Market Segments and Criteria for CRO Selection

• Overall Criteria for CRO Selection (Satisfiers)
• Areas for Improvement: Current Top Sources of Dissatisfaction
• Derived vs. Stated Importance
• Derived vs. Stated Importance: Strategic Issues
• Derived vs. Stated Importance: Secret Issues
• Derived vs. Stated Importance: Non-Issues
• Derived vs. Stated Importance: Basic Requirements
• Market Segments - The 3 Types of CRO Services Users
• Criteria for CRO Selection by Market Segment
• Scope and Intensity of Outsourcing by Market Segment
• Perceived Benefits and Motives for Outsourcing by Market Segment
• R&D Budget Size by Market Segment
• CRO Budget Share of the R&D Budget by Market Segment

CRO Preference Metrics

• The Importance of CRO Performance Metrics

Perceived Attributes of CROs

• Relative Perceived Strengths of CROs - The Broad Competitive Landscape

An Evaluation of 11 Large CROs

• Brand Awareness and Preference of 11 Large CROs
• Brand Awareness of 11 Large CROs
• Brand Preference of 11 Large CROs
• Awareness and Conversion to Preference: 11 Large CROs
• A Note: The Potential Impact of the Acquisition of Charles River's Capabilities by Kendle
• Service Category vs Price Category Matrix
• Service Category vs. Price Category Matrix: The Value Frontier
• Relative Perceived Strengths of 11 Large CROs

Clinical Trial Trends Across Regions

• Clinical Trials Per Region - Current and Future 2006-2011

Other Technology Requirements: Current and Future

• Biomarkers Biologics and Biotechnology Needs - Current and Future
• IT Capabilities Expected from CROs - Current and Future

Purchase Behavior Patterns and Trends

• Average No. of CROs Invited per Request for Proposal (RFP) - By Phase
• Share of Outstanding Budget Among Most Utilized CROs
• Utilization of Data Collection Capabilities in Phase II-IV Trials
• Status of Pre-Clinical Drug Discovery Outsourcing to CROs
• Emerging Factors for Future CRO Selection - Next 5 Years

About Frost & Sullivan

• Frost & Sullivan